Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)

Abstract:
Bexion Pharmaceuticals announced today that it has been awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI).

Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)

Covington, KY | Posted on October 11th, 2010

The grant entitled "SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme" was awarded September 28, 2010 and covers a two year period. This announcement from NCI follows their September 20, 2010 announcement selecting Bexion for a notable research collaboration with NCI's Nanotechnology Characterization Laboratory (NCL), part of a major program, the Alliance for Nanotechnology in Cancer, to advance the medical applications of nanotechnology.

Bexion's proprietary technology is based on Saposin C- dioleoylphosphatidylserine (dubbed "SapC-DOPS") and is a first-in-class nanovesicle therapeutic for the treatment of glioblastomas (GBM), pancreatic cancers, and other solid tumors. These nanovesicles have preferential affinity for phosphatidylserine-enriched membrane patches which appear to be common in many types of tumor cells and tumor neovasculature. Bexion's initial studies of SapC-DOPS nanovesicles have shown that
they induce apoptosis in cancer cell lines and also demonstrated in vivo efficacy in multiple tumor models.

The intent of this Phase II SBIR grant is to identify and select optimized SapC-DOPS formulations and treatment methods for glioblastoma multiforme, suitable for advancing Bexion's drug toward planned human testing. Upon the completion of these studies, Bexion expects to have compelling evidence to progress into clinical development.

"This Phase II award will expedite our goal to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma), a deadly and invasive brain tumor with no effective treatment," stated Dr. Ray Takigiku, Bexion's co-founder and CEO. "Of the 12,000 patients expected to be diagnosed with GBM this year, most will succumb within the first year. Clearly, there is an urgent demand for an efficacious anti-glioma drug."

This SBIR Phase II award is the fourth grant won by Bexion from the NCI. Past awards include Phase I grants for treating Metastatic Prostate, Pancreatic and Glioblastoma Multiforme.

####

About Bexion Pharma
Bexion Pharmaceuticals is focused on the development and commercialization of innovative cures for cancer. Initial products are based on a proprietary platform technology licensed from Cincinnati Children’s Hospital Medical Center. The technology has demonstrated potential for development as therapeutics, diagnostic and surgical imaging reagents, and as carriers for other pharmaceutical agents, such as oligonucleotides. For more information, visit www.bexionpharma.com.

For more information, please click here

Contacts:
Margaret van Gilse
VP, Business Development
Bexion Pharmaceuticals, LLC
632 Russell Street
Covington, KY 41011
Phone: (513) 833-7065

Copyright © Bexion Pharma

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Atomic Force Microscopes from Asylum Research Guide the Development of Thin Film Deposition and Etch Processes September 2nd, 2015

For 2-D boron, it's all about that base: Rice University theorists show flat boron form would depend on metal substrates September 2nd, 2015

Silk bio-ink could help advance tissue engineering with 3-D printers September 2nd, 2015

Phagraphene, a 'relative' of graphene, discovered September 2nd, 2015

Nanomedicine

Silk bio-ink could help advance tissue engineering with 3-D printers September 2nd, 2015

Using DNA origami to build nanodevices of the future September 1st, 2015

Efficiency of Nanodrug Containing Antibiotics in Treatment of Infectious Diseases Evaluated August 31st, 2015

Researchers use DNA 'clews' to shuttle CRISPR-Cas9 gene-editing tool into cells August 30th, 2015

Announcements

For 2-D boron, it's all about that base: Rice University theorists show flat boron form would depend on metal substrates September 2nd, 2015

Silk bio-ink could help advance tissue engineering with 3-D printers September 2nd, 2015

Phagraphene, a 'relative' of graphene, discovered September 2nd, 2015

A marine creature's magic trick explained: Crystal structures on the sea sapphire's back appear differently depending on the angle of reflection September 2nd, 2015

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

A marine creature's magic trick explained: Crystal structures on the sea sapphire's back appear differently depending on the angle of reflection September 2nd, 2015

RUSNANOPRIZE Directorate Announces New Deadline for Nominations Submission – September 11, 2015 September 1st, 2015

$200K Awarded to Develop In Vitro Lung Test for Toxicity of Inhaled Nanomaterials: In Vitro Lung Test Designed to Protect Human Health and Replace Animal Testing September 1st, 2015

Seeing quantum motion August 30th, 2015

Nanobiotechnology

A marine creature's magic trick explained: Crystal structures on the sea sapphire's back appear differently depending on the angle of reflection September 2nd, 2015

Using DNA origami to build nanodevices of the future September 1st, 2015

Researchers use DNA 'clews' to shuttle CRISPR-Cas9 gene-editing tool into cells August 30th, 2015

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic